Novo unveils new cardiometabolic data as it reports solid third-quarter profits

Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker revealed its third-quarter profits edged out expectations. First up, the Danish pharma giant said semaglutide met the primary endpoint ...